ALX Oncology Holdings Inc (ALXO) stock
Close on Nov 17, 2026Market cap $138.97MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $138.97M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.02
- Dividend yield
- –
- Free cash flow yield
- -51.05%
Fundamentals
- Net income
- -$80.89M
- EPS, diluted
- -$1.13
- Free cash flow
- -$70.95M
- Book value per share
- $1.00
- Diluted shares
- 136M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $1.00
- Open
- $0.99
- Day's range
- $0.96 – $1.04
- Volume
- 438,385
- Average volume (20 days)
- 1,078,565
- Index membership
- Russell 2000 (since Jun 2026)
- 52-week range
- $0.86 – $2.66
- RSI (14 days)
- 39.4
- Volatility (1 year)
- 90.7%
- Relative volume
- 0.39×
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALXO | S&P 500 | Difference | ALXO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.2% | -4.0% | −1.2 pts | ||
| 3 months | -49.0% | -5.0% | −44.0 pts | ||
| Year to date | -11.1% | +8.2% | −19.3 pts | ||
| 1 year | -35.6% | +11.2% | −46.8 pts | ||
| 3 years | -89.4% | +68.5% | −157.9 pts | -52.7% | +19.0% |
| 5 years | -97.7% | +67.3% | −164.9 pts | -52.8% | +10.8% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ALX Oncology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Update
- Results
About ALX Oncology
Pharmaceutical Preparations
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on advancing novel cancer therapies to prolong patient survival. Its clinical pipeline centers on two investigational candidates: evorpacept and ALX2004. Evorpacept is an engineered CD47-blocking fusion protein that pairs an affinity-enhanced extracellular domain of SIRPα with an inactivated Fc domain, designed to prevent hematologic toxicities while enabling the immune system to engulf cancer cells in combination with other anti-cancer treatments. The company evaluates evorpacept in clinical studies alongside targeted anti-cancer antibodies, small molecules, and checkpoint inhibitors, notably in combination with trastuzumab and chemotherapy for patients with metastatic HER2-positive breast cancer. ALX2004 is an antibody-drug conjugate targeting epidermal growth factor receptor (EGFR).
Company profile, executives and historyALX Oncology stock: common questions
What is ALX Oncology's stock price?
ALXO closed at $1.00 on Nov 17, 2026, up 0.50% on the day. Over the past 52 weeks it traded between $0.86 and $2.66.
What is ALX Oncology's market cap?
ALX Oncology was worth $138.97M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is ALXO's P/E ratio?
ALX Oncology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.13), so it has no meaningful P/E ratio.
Does ALX Oncology pay a dividend?
No. ALX Oncology has not paid a cash dividend over the last twelve months.
When does ALX Oncology report earnings next?
ALX Oncology's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has ALXO stock performed over the past year?
Including dividends, ALXO returned -35.6% over the past year, against +11.2% for the S&P 500.
How many ALXO shares are sold short?
6M shares were sold short at the latest FINRA report, 5.81% of the float, or 4.4 days of average trading volume.
Who are ALX Oncology's competitors?
Companies most similar to ALX Oncology by business, industry and size include ORIC, APVO, CTMX, PYXS, IDYA.
See a number that looks wrong?